TMB Results: The Future Use of Complex Biomarkers


 

Thank you to all who attended our virtual meeting! Click HERE to watch the meeting in full.
Click HERE to view the event recap.

 

Friends of Cancer Research Virtual Meeting

TMB Results:
The Future Use of Complex Biomarkers

 

Featuring an Opening Keynote with:
Ned Sharpless
Director, National Cancer Institute (NCI)

New Project Results Presentations by:
Mickey Williams

Director, Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research 


Lisa McShane
Associate Director, Division of Cancer Treatment and Diagnosis, NCI


Followed by a Live Panel Discussion with:

Nicholas Botwood, Vice President, Oncology Clinical Development, Bristol-Myers Squibb
Dave Fabrizio, Vice President, Translational Strategy, Foundation Medicine 
Reena Philip,
Director, Division of Molecular Genetics and Pathology, U.S. FDA 
Naiyer Rizvi,
Price Family Professor of Medicine; Director, Thoracic Oncology; Co-Director, Cancer Immunotherapy, Columbia University Irving Medical Center
Victor Weigman, Director, Translational Genomics, Q² Solutions

 

Thursday, July 23, 2020
12:00 PM EDT - 1:00 PM EDT

 

Friends of Cancer Research (Friends) is proud to announce part two in our virtual meeting series, TMB Results: The Future Use of Complex Biomarkers, as we feature the presentation of new, innovative findings. Building on our July 14th symposium, this virtual meeting will promo new results and dive deeper into the Friends of Cancer Research Tumor Mutational Burden (TMB) Harmonization Project and its latest findings. The virtual meeting will include impactful discussions from leaders in cancer research and drug development as to how this project’s framework can act as a blueprint for the development of additional harmonization initiatives for complex biomarkers.

 

For more information on the project, please click HERE.